Olga Maltseva Portfolio
Invests via Catalio Capital Management LP | Managed by George C. Petrocheilos, R. Jacob Vogelstein, Ph.D.
Invests via Catalio Capital Management LP
Managed by George C. Petrocheilos, R. Jacob Vogelstein, Ph.D.
Automatically Tracked
Olga Maltseva Profile
Olga Maltseva is a seasoned entrepreneur known for her innovative approach in the technology sector. With extensive experience in building and scaling tech startups, she has effectively merged strategic vision with operational excellence to drive growth. Her leadership has been pivotal in guiding companies through transformative stages, enabling them to navigate competitive landscapes successfully. Beyond her executive roles, Olga actively participates as an advisor, fostering emerging talent within the startup ecosystem while also contributing to investment dialogues focused on technology advancement and commercialization. She remains a significant figure within industry discussions centered around digital innovation.
Olga Maltseva is a seasoned entrepreneur known for her innovative approach in the technology sector. With extensive experience in building and scaling tech startups, she has effectively merged strategic vision with operational excellence to drive growth. Her leadership has been pivotal in guiding companies through transformative stages, enabling them to navigate competitive landscapes successfully. Beyond her executive roles, Olga actively participates as an advisor, fostering emerging talent within the startup ecosystem while also contributing to investment dialogues focused on technology advancement and commercialization. She remains a significant figure within industry discussions centered around digital innovation.
Investment Philosophy & Strategy
At the forefront of technology investment, Olga Maltseva embodies a vision for transformative growth through innovation. With an entrepreneurial mindset shaped by hands-on experience in building successful tech startups, she emphasizes strategic agility and operational refinement to capitalize on emerging opportunities. Her focus lies in identifying high-potential ventures that demonstrate scalability and disruptive capabilities within their respective markets. By championing new ideas and mentoring aspiring entrepreneurs, she nurtures a dynamic ecosystem conducive to technological advancement while facilitating productive dialogues around commercialization strategies. This holistic approach allows her to leverage both insights from her leadership journey and keen market awareness.
At the forefront of technology investment, Olga Maltseva embodies a vision for transformative growth through innovation. With an entrepreneurial mindset shaped by hands-on experience in building successful tech startups, she emphasizes strategic agility and operational refinement to capitalize on emerging opportunities. Her focus lies in identifying high-potential ventures that demonstrate scalability and disruptive capabilities within their respective markets. By championing new ideas and mentoring aspiring entrepreneurs, she nurtures a dynamic ecosystem conducive to technological advancement while facilitating productive dialogues around commercialization strategies. This holistic approach allows her to leverage both insights from her leadership journey and keen market awareness.
Disclaimer: This Portfolio is derived from and computed based on publicly available data from SEC filings.
Gain and growth charts are calculated per selected timeframe:
48.2%
Gain +0.31%
Monthly
1.82%
Yearly
24.14%
Drawdown
22.36%
$485.56M
Equity
Holdings
$485.56M
Investment
$462.22M
$200.27M
Profit +$1.59M
Realized
$176.94M
Unrealized
$23.34M
Dividends
$3.56M
Goals
Avg. 32% completed goals
Yearly
Gain > 5% 2026
Yearly
Gain < 20% 2026
Today
Compared To Yesterday
Gain
0.31%
Profit
$1.59M
Win %
44%
This Week
Compared To Last Week
Gain
0.33%
Profit
$1.59M
Win %
44%
This Month
Compared to last month
Gain
-4.91%
Profit
-$25.08M
Win %
44%
This Year
Compared to last year
Gain
-7.14%
Profit
-$37.35M
Win %
54%
PBLS Parabilis Medicines, Inc. Common Stock
+2.29%
+$461,464.08 
MGX Metagenomi Therapeutics, Inc.
+2.28%
+$9,733.47 
BBIO BridgeBio Pharma Inc.
+2.07%
+$646,158.22 
IMCR Immunocore Holdings plc ADR
+1.1%
+$50,335.3 
PTGX Protagonist Therapeutics, Inc.
+0.93%
+$137,770.71 
OM Outset Medical, Inc.
+0.73%
+$3,548.37 
HTFL HeartFlow Inc.
+0.7%
+$230,306.73 
CRVS Corvus Pharmaceuticals Inc.
+0.67%
+$75,662.16 
NTRA Natera, Inc.
+0.64%
+$212,027.8 
AVLN Avalyn Pharma Inc.
+0.61%
+$268,132.8 
IRON Disc Medicine, Inc.
+0.39%
+$46,221.36 
TARA Protara Therapeutics, Inc.
+0.21%
+$2,600.74 
KARD Kardigan Inc.
+0.16%
+$6,250 
SEPN Septerna, Inc.
+0.03%
+$5,361.52 
ASND Ascendis Pharma A/S
0%
$0 
ATAI AtaiBeckley Inc.
0%
$0 
ELDN Eledon Pharmaceuticals, Inc.
0%
$0 
BBOT BridgeBio Oncology Therapeutics, Inc.
0%
$0 
FDMT 4D Molecular Therapeutics, Inc.
-8.86%
-$494,816.7 
AXSM Axsome Therapeutics Inc.
-7.07%
-$476,298.06 
MLYS Mineralys Therapeutics, Inc.
-4.29%
-$596,824.24 
GPCR Structure Therapeutics Inc. American Depositary Shares
-3.37%
-$204,647 
BMY Bristol-Myers Squibb Company
-2.41%
-$627,700.72 
DNTH Dianthus Therapeutics Inc.
-2.23%
-$57,646.75 
RARE Ultragenyx Pharmaceutical Inc.
-1.88%
-$94,875.6 
MANE Veradermics, Incorporated
-1.47%
-$93,546.24 
KPTI Karyopharm Therapeutics Inc.
-1.45%
-$7,056.41 
ODTX Odyssey Therapeutics, Inc.
-1.43%
-$127,874.43 
JNJ Johnson & Johnson
-1.42%
-$527,993.41 
SNDX Syndax Pharmaceuticals, Inc.
-1.25%
-$206,668.66 
EW Edwards Lifesciences Corporation
-1.13%
-$127,273.06 
INCY Incyte Corp.
-1.04%
-$233,784.94 
DYN Dyne Therapeutics, Inc.
-0.95%
-$36,739.35 
FTH Faeth Therapeutics, Inc.
-0.88%
-$2,207.7 
GILD Gilead Sciences Inc.
-0.73%
-$309,707.24 
DFTX Definium Therapeutics Inc.
-0.67%
-$135,041.28 
GUTS Fractyl Health, Inc.
-0.46%
-$2,560.03 
HYPR Hyperfine, Inc. Class A Common Stock
-0.28%
-$2,640.12 
KLRA Kailera Therapeutics, Inc.
-0.23%
-$14,062.5 Events
Loading...
Dividends
Dividend Analysis
Loading...
No Data
| Trades 233 | Longs Won 130/233 55% | Profit Factor 2.37 |
| Profitability | Shorts Won 0/0 0% | Standard Deviation $4.21M |
| Average Win $2.67M | Best Trade (Jun 30) $39.91M | Sharpe Ratio -161.38 |
| Average Loss -$1.42M | Worst Trade (Jun 29) -$12.52M | Z-Score -1.66 (91.19%) |
| Commissions $0 | Avg. Trade Length 7m 1w 6d | Expectancy $859,548.34 |
| Loss Size | 100% | 90% | 80% | 70% | 60% | 50% | 40% | 30% | 20% | 10% |
| Probability of Loss | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | 0.72% |
| Consecutive Losing Trades | 341 | 307 | 273 | 239 | 205 | 171 | 137 | 102 | 68 | 34 |
Hover over the desired column for a detailed explanation.
Returns
Overall, Monthly| Symbol | Quantity | Cost | Value | Comm. | Profit ($) | Gain (%) | Change |
|---|---|---|---|---|---|---|---|
| ASND Ascendis Pharma A/S | 31,759 | $8.47M | $7.73M | - | -$741,572.17 | -8.75% | 0.0 |
| ATAI AtaiBeckley Inc. | 196,858 | $696,877.01 | $696,877.01 | - | - | - | 0.0 |
| AVLN Avalyn Pharma Inc. | 1.68M | $48.57M | $43.91M | - | -$4.66M | -9.59% | +0.614% |
| AXSM Axsome Therapeutics Inc. | 43,182 | $10.57M | $6.26M | - | -$4.31M | -40.74% | -7.067% |
| BBIO BridgeBio Pharma Inc. | 455,041 | $33.8M | $31.84M | - | -$1.95M | -5.78% | +2.071% |
| BBOT BridgeBio Oncology Therapeutics, Inc. | 318,407 | $2.43M | $846,962.62 | - | -$1.58M | -65.09% | 0.0 |
| BMY Bristol-Myers Squibb Company | 412,961 | $22.28M | $25.39M | - | $3.11M | 13.98% | -2.413% |
| CRVS Corvus Pharmaceuticals Inc. | 1.08M | $15.87M | $11.46M | - | -$4.41M | -27.81% | +0.665% |
| DFTX Definium Therapeutics Inc. | 562,672 | $10.63M | $19.94M | - | $9.3M | 87.46% | -0.673% |
| DNTH Dianthus Therapeutics Inc. | 32,941 | $718,113.81 | $2.53M | - | $1.81M | 252.2% | -2.228% |
| DYN Dyne Therapeutics, Inc. | 244,929 | $4.79M | $3.83M | - | -$965,020.06 | -20.14% | -0.951% |
| ELDN Eledon Pharmaceuticals, Inc. | 1.7M | $4.44M | $3.9M | - | -$537,779.84 | -12.12% | 0.0 |
| EW Edwards Lifesciences Corporation | 124,778 | $10.64M | $11.11M | - | $476,651.96 | 4.48% | -1.132% |
| FDMT 4D Molecular Therapeutics, Inc. | 471,254 | $5.43M | $5.09M | - | -$339,302.88 | -6.25% | -8.861% |
| FTH Faeth Therapeutics, Inc. | 14,718 | $126,280 | $249,175.74 | - | $122,895.74 | 97.32% | -0.878% |
| GILD Gilead Sciences Inc. | 269,309 | $33.43M | $42.02M | - | $8.59M | 25.69% | -0.732% |
| GPCR Structure Therapeutics Inc. American Depositary Shares | 276,550 | $6.79M | $5.86M | - | -$925,316.81 | -13.64% | -3.374% |
| GUTS Fractyl Health, Inc. | 512,006.17 | $9.59M | $550,406.63 | - | -$9.04M | -94.26% | -0.463% |
| HTFL HeartFlow Inc. | 583,055 | $15.63M | $33.3M | - | $17.66M | 112.97% | +0.697% |
| HYPR Hyperfine, Inc. Class A Common Stock | 1.32M | $1.22M | $955,709.66 | - | -$269,031.71 | -21.97% | -0.275% |
No Data
Option values are updated at end of day.
No Data
No Data
Option values are updated at end of day.
No Data
No Data
No Data
No Data
FAQ
Which stocks have generated the highest profits for Olga Maltseva?
The largest contributions to the portfolio's profits come from the following stocks: Dianthus Therapeutics Inc - $47.31M, BridgeBio Pharma Inc - $22.82M, Structure Therapeutics Inc. American Depositary Shares - $16.72M, Eli Lilly and Company - $16.14M, and Ascendis Pharma A/S - $15.85M. These positions have been the main drivers of growth and have significantly impacted the investor's overall performance.
Which stocks have generated the largest losses for this investor?
The largest losses in the portfolio are associated with the following stocks: Soleno Therapeutics, Inc - $18.18M, Boston Scientific Corp - $13.75M, Septerna, Inc - $9M, MoonLake Immunotherapeutics Class A Ordinary Shares - $5.58M, and Veracyte, Inc - $4.88M. These positions have had the most negative impact on overall performance and highlight the weaker areas of the portfolio.
What dividends does Olga Maltseva's portfolio generate?
The portfolio generates substantial dividend income, with a total of $3.56M earned over time. The largest contributors to dividend income include Bristol-Myers Squibb Company - $1.5M, Gilead Sciences Inc - $771,702.57, Becton, Dickinson and Company - $366,683.2, Johnson & Johnson - $343,279.64, and AbbVie Inc - $253,927.76. This indicates that dividends play a meaningful role in the investor's overall strategy.
How stable are Olga Maltseva's monthly returns?
Olga Maltseva's monthly returns appear quite volatile. The gap between stronger and weaker months is meaningful, which suggests that the strategy can experience noticeable swings over relatively short periods. For users assessing this profile, that usually means returns may be attractive over time, but the path can be uneven and harder to tolerate during weaker periods.
Can Olga Maltseva's strategy be considered aggressive or moderate?
Olga Maltseva's strategy can be described as moderate. It balances growth potential with risk management, showing a willingness to accept some volatility while still maintaining a relatively structured and diversified approach.
Should beginners follow Olga Maltseva's strategy?
Olga Maltseva's strategy is probably not ideal for beginners. The combination of risk, volatility, or portfolio complexity may make it harder to follow and understand without prior experience. Users who are new to investing may find it challenging to replicate or tolerate the performance swings.
2026 © Marketlog. All Rights Reserved.
